Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety

Chronic Respiratory Disease

Volumn 8, Issue 2, 2011, Pages 109-118

  Pickering, Elspeth E ^a,b,d   Semple, Stephen J ^c   Nazir, Muhummad S ^c   Murphy, Kevin ^b   Snow, Thomas M ^a   Cummin, Andrew R ^b   Moosavi, Shakeeb H ^c   Guz, Abraham ^c   Holdcroft, Anita ^c  

^a North Thames Regional Office   (United Kingdom)

^b NATIONAL HEALTH SERVICE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

breathlessness; cannabinoids; carbon dioxide; COPD; human

Indexed keywords

CANNABIS; CARBON DIOXIDE; PLACEBO; TETRAHYDROCANNABINOL;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; END TIDAL CARBON DIOXIDE TENSION; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VISUAL ANALOG SCALE;

ADULT; AGED; CANNABIDIOL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSPNEA; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHOTROPIC DRUGS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY VENTILATION; RESPIRATORY RATE; SENSATION; TETRAHYDROCANNABINOL;

EID: 79957517761     PISSN: 14799723     EISSN: 14799731     Source Type: Journal    
DOI: 10.1177/1479972310391283     Document Type: Article

References (33)

1. Mitchell-Heggs P., Murphy K., Minty K., et al. Diazepam in the treatment of dyspnoea in the 'pink puffer' syndrome. Q J Med 1980 ; 49: 9-20. (Pubitemid 10039097)
2. Muers MF Opioids for dyspnoea. Thorax 2002 ; 57: 92-923.
3. Banzett RB, Henrietta E., Mulnier HE, et al. Breathlessness in humans activates insular cortex. Brain Imaging 2000 ; 11: 2117-2120. (Pubitemid 30485546)
4. Peiffer C., Poline J., Thivard L., Aubier M., and Samson Y. Neural substrates for the perception of acutely induced dyspnea. Am J Respir Crit Care Med 2001 ; 163: 951-957. (Pubitemid 32275870)
5. Evans KC, Banzett RB, Adams L., McKay L., Frackowiak RSJ, and Corfield DR fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 2002 ; 88: 1500-1511. (Pubitemid 35025403)
6. Von Leupoldt A., Sommer T., Kegat et al. The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala. Am J Respir Crit Care Med 2008 ; 177: 1026-1032. (Pubitemid 351717598)
7. Robbe D., Kopf M., Remaury A., Bockaett J., and Manzoni OJ Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. PNAS 2002 ; 99: 8384-8388. (Pubitemid 34651061)
8. Pertwee RG Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997 ; 74: 129-180. (Pubitemid 27337346)
9. Herkenham M., Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. PNAS 1990 ; 87: 1932-1936.
10. Bellville JW, Swanson GD, and Aqleh KA Respiratory effects of delta-9-tetrahydrocannabinol. Clin Pharm Ther 1975 ; 17: 541-548.
11. Johnstone RE, Lief PL, Kulp RA, and Smith TC Combination of delta-9-tetrahydrocannabinol with oxymorphone or pentobarbital: effects on ventilatory control and cardiovascular dynamics. Anesthesiology 1975 ; 42: 674-684.
12. Malit LA, Johnstone RE, Bourke DI, et al. Intravenous delta-9-Tetrahydrocannabinol: effects on ventilatory control and cardiovascular dynamics. Anesthesiology 1973 ; 42: 666-673.
13. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, and Wiethe KE Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 1992 ; 12: 750-758.
14. Karniol IG and Carlini EA Pharmacological interaction between cannabidiol and delta-9-tetrahydrocannabinol. Psychopharmacologia 1973 ; 33: 53-70.
15. Zuardi AW Cannabidiol: from an inactive cannabinoid to a drug with widespread spectrum of action. Rev Bras Psiquiatr. 2008 ; 30: 271-280.
16. Zuardi AW, Shirakawa I., Finkelarb E., and Karanol IG Action of cannabidiol on the anxiety and other effects produced by delta-9-THC in normal subjects. Psychopharmacology 1982 ; 76: 245-250. (Pubitemid 12129400)
17. Lefant C. and Khaltaev N. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. National Institutes of health and National Heart, Lung, and Blood Institute. Publication Number 2701, 2001: 14.
18. Zigmond AS and Snaith RP The Hospital Anxiety and Depression scale. Acta Psychiatr Scand 1983 ; 67: 361-370. (Pubitemid 13098606)
19. Lansing RW, Moosavi SH, and Banzett RB Measurement of dyspnea: word labelled visual analogue scale vs. verbal ordinal scale. Resp Phys Neurobiol 2003 ; 134: 77-83. (Pubitemid 36279432)
20. Banzett RB, Lansing RW, Brown R., et al. 'Air hunger' from increased PCO2 persists after complete neuromuscular block in humans. Respir Physiol 1990 ; 81: 1-17.
21. Fenn WO and Craig JR Effect of CO2 administration using a new method of administrating CO2. J Appl Physiol 1963 ; 18: 1023-1024.
22. Speilberger CD State-trait anxiety inventory for adults. Palo Alto, CA: Mind-Garden, 1983.
23. Speilberger CD, Gorsuch RL, and Lushene R. Test for the state-trait anxiety inventory. Palo Alto, CA: Consulting Psychologists Press, 1970.
24. Thayer RE The biopsychology of mood and arousal. New York: Oxford University Press, 1989.
25. Hartung TK, Rolfe S., Wilson AM, Al-Khairalla MZH, and Winter JH Dose-escalation and safety study of cannabis based medicinal extract in patients with severe COPD [Abstract]. Proc Am Thorac Soc 2005 ; 2: A544.
26. Spengler CM, Czeisler CA, and Shea SA An endogenous circadian rhythm of respiratory control in humans. J Physiol 2000 ; 526: 683-684.
27. Holdcroft A., Maze M., Dore C., Tebbs S., and Tompson S. A multidose-escalation study of the analgesic and adverse effects of an oral cannabis extract (cannador) for post-operative pain management. Anaesthesiology 2006 ; 104: 1040-1046.
28. Smith J., Albert P., Bertella E., Lester J., and Calverley P. Qualitative aspects of breathlessness in health and disease. Thorax 2009 ; 64: 713-718.
29. Banzett RB, Pedersen SH, Schwartzstein RM, and Lansing RW The affective dimensions of laboratory dyspnea. Air hunger is more unpleasant than work/effort. Amer J Respir Crit Care Med 2008 ; 177: 1384-1390. (Pubitemid 351860917)
30. Lansing RW, Gracely RH, and Banzett RB The multiple dimensions of dyspnoea: Review and hypotheses. Respiratory Physiology and Neurobiology 2009 ; 167: 53-60.
31. Yorke J., Moosavi SH, Shuldham C., and Jones PW Quantification of dyspnoea using descriptors: Dyspnoea-12. Thorax 2010 ; 65: 21-26.
32. Laviolette M. and Belanger J. Role of prostaglandins in marihuana-induced bronchodilation. Respiration 1986 ; 49: 10-15. (Pubitemid 16212895)
33. Abboud RT and Sanders HD Effect of oral administration of delta-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Chest 1976 ; 70: 480-485.